[Fundamental and clinical studies of XXXX suppositories in pediatrics].

@entity1 @entity3617 @entity2346 @entity55 @entity7551 @entity294 @entity5389 @entity272 @entity8933 @entity293
Fundamental and clinical studies were carried out on @entity8933 suppository (CZX-S), and the following results were obtained in pediatrics. In 4 @entity1 of the CZX-S 125 mg-administered group (9.4-9.9 mg/kg), the serum concentration of CZX reached a peak of 5.55 micrograms/ml on the average, 30 minutes after dosing, i.e. at the time of initial blood collection, and decreased gradually to 0.20 microgram/ml 6 hours after dosing. The half-life was 1.09 hours. In 5 @entity1 of the CZX-S 250 mg-administered group (8.4-18.1 mg/kg), the serum concentration of CZX peaked at 7.07 micrograms/ml on the average and then gradually declined to 0.16 microgram/ml 6 hours after dosing. The half-life was 1.00 hour. The urinary recovery rate varied as widely as 6.5-38.0% in all the @entity1 of both groups. CZX-S was given to total 19 @entity1 ; 8 @entity1 with @entity293 ( @entity293 ), 3 with @entity7551 or @entity5389 , 4 with @entity3617 , 2 with @entity55 , 1 with @entity2346 media and 1 with staphylococcal scalding @entity272 . The overall effect of CZX-S in 15 @entity1 was "effective" or better response, with an effectiveness rate of 83.3%, except one who discontinued the drug because of side effects. CZX-S was given to most of the @entity1 weighing 15 kg or higher in a dose of 250 mg 3-4 times a day and frequently to @entity1 weighing less than 15 kg in a dose of 125 mg 3-4 times a day. As to side effects, slight @entity294 was encountered in 1 @entity1 . Laboratory examinations disclosed an increase in GOT in 1 @entity1 , which returned to normal after continual insertion of the suppository.
